UNLABELLED: Sex chromosome tetrasomy and pentasomy conditions occur in 1:18,000-1:100,000 male births. While often compared with 47,XXY/Klinefelter syndrome because of shared features including tall stature and hypergonadotropic hypogonadism, 48,XXYY, 48,XXXY and 49,XXXXY syndromes are associated with additional physical findings, congenital malformations, medical problems and psychological features. While the spectrum of cognitive abilities extends much higher than originally described, developmental delays, cognitive impairments and behavioural disorders are common and require strong treatment plans. Future research should focus on genotype-phenotype relationships and the development of evidence-based treatments. CONCLUSION: The more complex physical, medical and psychological phenotypes of 48,XXYY, 48,XXXY and 49,XXXXY syndromes make distinction from 47,XXY important; however, all of these conditions share features of hypergonadotropic hypogonadism and the need for increased awareness, biomedical research and the development of evidence-based treatments.
UNLABELLED: Sex chromosome tetrasomy and pentasomy conditions occur in 1:18,000-1:100,000 male births. While often compared with 47,XXY/Klinefelter syndrome because of shared features including tall stature and hypergonadotropic hypogonadism, 48,XXYY, 48,XXXY and 49,XXXXY syndromes are associated with additional physical findings, congenital malformations, medical problems and psychological features. While the spectrum of cognitive abilities extends much higher than originally described, developmental delays, cognitive impairments and behavioural disorders are common and require strong treatment plans. Future research should focus on genotype-phenotype relationships and the development of evidence-based treatments. CONCLUSION: The more complex physical, medical and psychological phenotypes of 48,XXYY, 48,XXXY and 49,XXXXY syndromes make distinction from 47,XXY important; however, all of these conditions share features of hypergonadotropic hypogonadism and the need for increased awareness, biomedical research and the development of evidence-based treatments.
Authors: D Stemkens; T Roza; L Verrij; H Swaab; M K van Werkhoven; B Z Alizadeh; R J Sinke; J C Giltay Journal: Clin Genet Date: 2006-07 Impact factor: 4.438
Authors: Jay N Giedd; Liv S Clasen; Gregory L Wallace; Rhoshel K Lenroot; Jason P Lerch; Elizabeth Molloy Wells; Jonathan D Blumenthal; Jean E Nelson; Julia W Tossell; Catherine Stayer; Alan C Evans; Carole A Samango-Sprouse Journal: Pediatrics Date: 2007-01 Impact factor: 7.124
Authors: Anne M Wikström; Jodie N Painter; Taneli Raivio; Kristiina Aittomäki; Leo Dunkel Journal: Clin Endocrinol (Oxf) Date: 2006-07 Impact factor: 3.478
Authors: Anthony J Swerdlow; Minouk J Schoemaker; Craig D Higgins; Alan F Wright; Patricia A Jacobs Journal: J Natl Cancer Inst Date: 2005-08-17 Impact factor: 13.506
Authors: Kazutoyo Osoegawa; David M Iovannisci; Bin Lin; Christina Parodi; Kathleen Schultz; Gary M Shaw; Edward J Lammer Journal: Am J Med Genet A Date: 2013-10-11 Impact factor: 2.802
Authors: Talia Thompson; Susan Howell; Shanlee Davis; Rebecca Wilson; Jennifer Janusz; Richard Boada; Laura Pyle; Nicole Tartaglia Journal: Am J Med Genet C Semin Med Genet Date: 2020-05-25 Impact factor: 3.908
Authors: Michael D Keller; Teresa Sadeghin; Carole Samango-Sprouse; Jordan S Orange Journal: Am J Med Genet C Semin Med Genet Date: 2013-01-23 Impact factor: 3.908